Skip to content
Screener

Bruker BRKR Financing Cash Flow

Financing Cash Flow at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
-$1.57B-58.5%
Danaher logo
DanaherDHR
$7.27B+3,045%
TEC
Bio-TechneTECH
-$42.72M+37.2%
WAT
Waters CorporationWAT
-$123M-9,547%
Agilent Technologies logo
Agilent TechnologiesA
-$144M-24.1%
908 Devices logo
908 DevicesMASS
-$2.17M-1,047%

Other financials

Income statement

See full
Revenue$838.5M+5.2%
Gross profit$416.0M+16.2%
Operating income-$65.3M-649%
Net income-$52.0M-784%
EPS (diluted)-$0.41-920%

Balance sheet

See full
Cash & equivalents$189.1M+96.6%
Total debt$1.8B-25.1%
Total equity$2.4B+31.9%
Total assets$6.1B-4.5%

Cash flow

See full
Operating cash flow-$77.4M+39.3%
CapEx$28.8M+35.2%
Free cash flow-$106.2M+28.6%

Valuation

See full
Market cap$7.99B+71.7%
Enterprise value$9.62B+37.7%
P/S2.3×+0.9×

Profitability

See full
Gross margin46.4%-1.8pp
Operating margin-0.9%-6.2pp
Net margin-0.6%-10.0pp
FCF margin2.7%+1.3pp

Returns & leverage

See full
Return on equity-1%-21.2pp
Debt / equity0.8×-0.6×
Current ratio1.8×+0.2×

Where this comes from

Reported directly by Bruker in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Bruker’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:09 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-211889
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Payment of dividends to common shareholders(7.6)(7.7)
Repurchase of common stock(10.0)
Other financing activities, net(5.0)(0.7)
Net cash used in financing activities(204.9)(51.2)
Effect of exchange rate changes on cash, cash equivalents and restricted cash7.913.3
Net (decrease) increase in cash, cash equivalents and restricted cash(165.5)1.0
Cash, cash equivalents and restricted cash at beginning of period303.1186.7
Cash, cash equivalents and restricted cash at end of period$137.6$187.7

ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FAQ

What is Bruker's financing cash flow?
Bruker (BRKR) reported financing cash flow of -$204.9M in Q1 2026.
How has Bruker's financing cash flow changed year-over-year?
Bruker's financing cash flow decreased by 300.2% year-over-year, from -$51.2M to -$204.9M.
What is the long-term trend for Bruker's financing cash flow?
Over 2 years (2021 to 2023), Bruker's financing cash flow has grown at a -22.1% compound annual growth rate (CAGR), from $318.7M to -$193.4M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Bruker's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude